Spark Therapeutics has announced that it has acquired Dublin, Ireland-based Genable Technologies, a private gene therapy innovator.
Spark and Genable have collaborated since 2014 in the development of Genable's therapeutic program targeting one of the most prevalent forms of inherited retinal disease.
With the acquisition, Spark acquires RhoNova™, a potential treatment targeting rhodopsin-linked autosomal dominant retinitis pigmentosa, an IRD that routinely leads to visual impairment and in the most severe cases, to blindness. RhoNova has been granted Orphan Drug Designation in both the U.S. and Europe in addition to the Advanced Therapy Medicinal Product designation from the European Medicines Agency.
Read the Spark press release